These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2406 related articles for article (PubMed ID: 15099124)

  • 1. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
    Culy CR; Jarvis B
    Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
    Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST
    Pharmacoeconomics; 2003; 21(11):819-37. PubMed ID: 12859222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
    Palmer AJ; Roze S; Lammert M; Valentine WJ; Minshall ME; Nicklasson L; Gall MA; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S41-51. PubMed ID: 15324515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.
    Foster RH; Plosker GL
    Pharmacoeconomics; 2000 Sep; 18(3):289-306. PubMed ID: 11147395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.
    Scheen AJ
    Drug Saf; 2005 Jul; 28(7):601-631. PubMed ID: 27722966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
    Landgraf R
    Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
    Moses R
    Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide: a review of its use in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2012 Jan; 72(2):249-72. PubMed ID: 22268393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
    Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
    Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meglitinide analogues for type 2 diabetes mellitus.
    Black C; Donnelly P; McIntyre L; Royle PL; Shepherd JP; Thomas S
    Cochrane Database Syst Rev; 2007 Apr; 2007(2):CD004654. PubMed ID: 17443551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 121.